
FDA policy
FDA proposes moving cancer drug-matching IHC tests off the PMA track to 510(k)
Under a proposed order, immunohistochemistry tests used to select patients for specific cancer drugs, including HER2 and PD-L1 companion diagnostics, would move from Class III to Class II. New tests would need 510(k) clearance rather than a PMA.

